Revolution Medicines' pan-RAS (on) inhibitor daraxonrasib has delivered a big result in pancreatic cancer, with a doubling in overall survival compared to chemotherapy in the highly anticipated ...

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows its value in an adjuvant lung cancer setting. The LIBRETTO-432 trial showed ...

The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...

Pfizer has signed a strategic-level R&D alliance with Innovent Biologics, worth $10.5 billion and spanning a dozen programmes in oncology, in another sign of China's emergence as a life sciences R&D ...

This week, 28 th-29 th May, the Veeva R&D and Quality Summit took place in Copenhagen, Denmark. Focused on innovating together, and together advancing the industry, the Summit this year highlighted an ...

The UK's National Screening Committee has concluded its review of prostate cancer screening in the UK, saying that the harms of a large-scale, national programme would outweigh the benefits. The ...

The initiative is part of the Pharmacy First programme, first introduced in 2024, which allowed pharmacists who hold an independent prescribing qualification to prescribe drugs for sore throat, ...

AI has implications across the value chain in oncology, including in the diagnostics space, where agentic AI is making it easier to access and understand genomic data – an advance with applications in ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, can achieve a functional cure in 19% of patients, ...

As clinical research sites come under growing operational pressure, sponsors and CROs are being challenged to rethink how studies are designed and supported. Protocols are becoming more complex.